<p>Repare Therapeutics Inc.（納斯達克代碼：RPTX - 獲取免費報告）在覆蓋該公司的七家券商中獲得了 “持有” 的平均推薦，Marketbeat Ratings 報告稱。一位分析師對該股票給予了賣出評級，四位分析師給予了持有評級，另外兩位分析師給予了買入評級。在過去一年中，發佈報告的券商對該股票的平均一年目標價為 3.50 美元。</p>
<p>RPTX 已成為幾份分析師報告的主題。華爾街禪在 11 月 15 日（星期六）的報告中將 Repare Therapeutics 的股票評級上調至 “持有”。TD Cowen 在 11 月 17 日（星期一）的研究報告中將 Repare Therapeutics 的評級從 “強力買入” 下調至 “持有”。Weiss Ratings 在 10 月 8 日（星期三）的報告中重申了對 Repare Therapeutics 股票的 “賣出（d-）” 評級。HC Wainwright 在 10 月 27 日（星期一）的報告中將 Repare Therapeutics 的目標價從 5.00 美元下調至 3.00 美元，並對該股票給予了 “買入” 評級。最後，Cowen 在一份研究報告中將 Repare Therapeutics 的評級下調至 “持有”。</p>
<p>獲取 <strong>Repare Therapeutics</strong> 警報：</p>
<p><strong>獲取我們關於 Repare Therapeutics 的最新研究報告</strong></p>
<h2>機構投資者對 Repare Therapeutics 的看法</h2>
<p>幾家對沖基金最近買入和賣出了該公司的股票。Quinn Opportunity Partners LLC 在第二季度以 56,000 美元的估值收購了 Repare Therapeutics 的新頭寸。Affinity Asset Advisors LLC 在第一季度將其在 Repare Therapeutics 的持倉增加了 100.0%。Affinity Asset Advisors LLC 現在擁有 200,000 股該公司的股票，價值 197,000 美元，在此期間又購買了 100,000 股。Acadian Asset Management LLC 在第一季度將其在 Repare Therapeutics 的股份增加了 35.6%。Acadian Asset Management LLC 現在擁有 640,332 股該公司的股票，價值 624,000 美元，在上個季度又收購了 168,230 股。Squarepoint Ops LLC 在第三季度以 115,000 美元的估值收購了 Repare Therapeutics 的新股份。最後，Rangeley Capital LLC 在第二季度以約 494,000 美元的估值購買了 Repare Therapeutics 的新股份。目前 85.09% 的股票由機構投資者和對沖基金持有。</p>
<h2>Repare Therapeutics 股票上漲 0.5%</h2>
<p>Repare Therapeutics 股票在週五的交易中上漲了 0.01 美元，達到 2.11 美元。該股票的交易量為 1,178,199 股，而其平均交易量為 1,054,180 股。該公司的 50 日移動平均線為 1.82 美元，200 日移動平均線為 1.61 美元。Repare Therapeutics 的 52 周低點為 0.89 美元，52 周高點為 4.07 美元。該公司的市值為 9071 萬美元，市盈率為-1.25，貝塔值為 1.06。</p>
<p>Repare Therapeutics（納斯達克代碼：RPTX - 獲取免費報告）最近在 11 月 14 日（星期五）發佈了季度財報。該公司報告每股收益（EPS）為 0.08 美元，超過分析師共識預期的（0.35 美元）0.43 美元。該公司季度收入為 1162 萬美元，而共識預期為 750 萬美元。整體來看，分析師預測 Repare Therapeutics 在當前財政年度將發佈-2.04 的每股收益。</p>
<h2>Repare Therapeutics 公司簡介</h2>
<p>（獲取免費報告）</p>
<p>Repare Therapeutics Inc. 是一家臨牀階段的精準腫瘤學公司，致力於通過在加拿大和美國使用其合成致死方法來發現和開發治療藥物。它利用其 SNIPRx，這是一種專有的、全基因組的、基於 CRISPR 的平台，來發現、驗證並建立以 SL 為基礎的治療藥物管道，重點關注基因組不穩定性，包括 DNA 損傷修復。</p>
<h2>精選故事</h2>
<ul>
<li>我們更看好的五隻股票，而不是 Repare Therapeutics</li>
<li>銀行股票 - 最值得投資的銀行股票</li>
<li>收益投資者注意：這隻 REIT 正在打折出售</li>
<li>ESG 股票，投資者需要知道的事項</li>
<li>Rocket Lab 剛經歷了第一次真正的崩潰——反彈可能會更大</li>
<li>股息捕捉策略：您需要知道的事項</li>
<li>MarketBeat 週迴顧 – 11/17 - 11/21</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9UlBUWA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9UlBUWA"/></p>
<p><em>此即時新聞警報由敍事科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快的報道和公正的覆蓋。請將任何問題或意見發送至 contact@marketbeat.com。</em></p>
<h2>你現在應該投資 1,000 美元在 Repare Therapeutics 嗎？</h2>
<p>在考慮 Repare Therapeutics 之前，您需要聽聽這個。</p>
<p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦的股票。MarketBeat 已識別出五隻頂級分析師正在悄悄向客户推薦的股票，建議在更廣泛的市場注意到之前立即購買……而 Repare Therapeutics 並不在名單上。</p>
<p>雖然 Repare Therapeutics 目前在分析師中獲得了持有評級，但頂級分析師認為這五隻股票更值得購買。</p>
<p>查看這五隻股票</p>

RPTX

<p>Repare Therapeutics Inc.（納斯達克代碼：RPTX）獲得了七家券商的 “持有” 共識評級。該股票有一個賣出評級、四個持有評級和兩個買入評級。平均一年目標價為 3.50 美元。機構投資者和對沖基金持有該股票的 85.09%。該公司報告了上一季度每股收益為 0.08 美元，超出預期。Repare Therapeutics 是一家臨牀階段的精準腫瘤學公司，採用合成致死的方法</p>

<p>Repare Therapeutics Inc. (NASDAQ:RPTX - Get Free Report) has been given an average recommendation of &#34;Hold&#34; by the seven brokerages that are covering the company, Marketbeat Ratings reports. One analyst has rated the stock with a sell rating, four have issued a hold rating and two have issued a buy rating on the company. The average 1-year target price among brokers that have issued a report on the stock in the last year is $3.50.</p>
<div class="lb-trans"><p>Repare Therapeutics Inc.（納斯達克代碼：RPTX - 獲取免費報告）在覆蓋該公司的七家券商中獲得了 “持有” 的平均推薦，Marketbeat Ratings 報告稱。一位分析師對該股票給予了賣出評級，四位分析師給予了持有評級，另外兩位分析師給予了買入評級。在過去一年中，發佈報告的券商對該股票的平均一年目標價為 3.50 美元。</p>
</div><p>RPTX has been the topic of several analyst reports. Wall Street Zen raised shares of Repare Therapeutics to a &#34;hold&#34; rating in a report on Saturday, November 15th. TD Cowen lowered Repare Therapeutics from a &#34;strong-buy&#34; rating to a &#34;hold&#34; rating in a research note on Monday, November 17th. Weiss Ratings reaffirmed a &#34;sell (d-)&#34; rating on shares of Repare Therapeutics in a report on Wednesday, October 8th. HC Wainwright reduced their target price on Repare Therapeutics from $5.00 to $3.00 and set a &#34;buy&#34; rating on the stock in a report on Monday, October 27th. Finally, Cowen cut Repare Therapeutics to a &#34;hold&#34; rating in a research note on Monday.</p>
<div class="lb-trans"><p>RPTX 已成為幾份分析師報告的主題。華爾街禪在 11 月 15 日（星期六）的報告中將 Repare Therapeutics 的股票評級上調至 “持有”。TD Cowen 在 11 月 17 日（星期一）的研究報告中將 Repare Therapeutics 的評級從 “強力買入” 下調至 “持有”。Weiss Ratings 在 10 月 8 日（星期三）的報告中重申了對 Repare Therapeutics 股票的 “賣出（d-）” 評級。HC Wainwright 在 10 月 27 日（星期一）的報告中將 Repare Therapeutics 的目標價從 5.00 美元下調至 3.00 美元，並對該股票給予了 “買入” 評級。最後，Cowen 在一份研究報告中將 Repare Therapeutics 的評級下調至 “持有”。</p>
</div><p>Get <strong>Repare Therapeutics</strong> alerts:</p>
<div class="lb-trans"><p>獲取 <strong>Repare Therapeutics</strong> 警報：</p>
</div><p><strong>Get Our Latest Research Report on Repare Therapeutics</strong></p>
<div class="lb-trans"><p><strong>獲取我們關於 Repare Therapeutics 的最新研究報告</strong></p>
</div><h2>Institutional Investors Weigh In On Repare Therapeutics</h2>
<div class="lb-trans"><h2>機構投資者對 Repare Therapeutics 的看法</h2>
</div><p>Several hedge funds have recently bought and sold shares of the company. Quinn Opportunity Partners LLC acquired a new position in shares of Repare Therapeutics in the 2nd quarter valued at $56,000. Affinity Asset Advisors LLC boosted its position in shares of Repare Therapeutics by 100.0% during the first quarter. Affinity Asset Advisors LLC now owns 200,000 shares of the company's stock worth $197,000 after buying an additional 100,000 shares during the period. Acadian Asset Management LLC grew its stake in shares of Repare Therapeutics by 35.6% during the 1st quarter. Acadian Asset Management LLC now owns 640,332 shares of the company's stock worth $624,000 after acquiring an additional 168,230 shares in the last quarter. Squarepoint Ops LLC acquired a new stake in Repare Therapeutics in the 3rd quarter valued at $115,000. Finally, Rangeley Capital LLC bought a new stake in Repare Therapeutics during the second quarter worth about $494,000. 85.09% of the stock is currently owned by institutional investors and hedge funds.</p>
<div class="lb-trans"><p>幾家對沖基金最近買入和賣出了該公司的股票。Quinn Opportunity Partners LLC 在第二季度以 56,000 美元的估值收購了 Repare Therapeutics 的新頭寸。Affinity Asset Advisors LLC 在第一季度將其在 Repare Therapeutics 的持倉增加了 100.0%。Affinity Asset Advisors LLC 現在擁有 200,000 股該公司的股票，價值 197,000 美元，在此期間又購買了 100,000 股。Acadian Asset Management LLC 在第一季度將其在 Repare Therapeutics 的股份增加了 35.6%。Acadian Asset Management LLC 現在擁有 640,332 股該公司的股票，價值 624,000 美元，在上個季度又收購了 168,230 股。Squarepoint Ops LLC 在第三季度以 115,000 美元的估值收購了 Repare Therapeutics 的新股份。最後，Rangeley Capital LLC 在第二季度以約 494,000 美元的估值購買了 Repare Therapeutics 的新股份。目前 85.09% 的股票由機構投資者和對沖基金持有。</p>
</div><h2>Repare Therapeutics Stock Up 0.5%</h2>
<div class="lb-trans"><h2>Repare Therapeutics 股票上漲 0.5%</h2>
</div><p>Repare Therapeutics stock traded up $0.01 during trading hours on Friday, hitting $2.11. The stock had a trading volume of 1,178,199 shares, compared to its average volume of 1,054,180. The company has a 50-day moving average of $1.82 and a two-hundred day moving average of $1.61. Repare Therapeutics has a fifty-two week low of $0.89 and a fifty-two week high of $4.07. The company has a market cap of $90.71 million, a PE ratio of -1.25 and a beta of 1.06.</p>
<div class="lb-trans"><p>Repare Therapeutics 股票在週五的交易中上漲了 0.01 美元，達到 2.11 美元。該股票的交易量為 1,178,199 股，而其平均交易量為 1,054,180 股。該公司的 50 日移動平均線為 1.82 美元，200 日移動平均線為 1.61 美元。Repare Therapeutics 的 52 周低點為 0.89 美元，52 周高點為 4.07 美元。該公司的市值為 9071 萬美元，市盈率為-1.25，貝塔值為 1.06。</p>
</div><p>Repare Therapeutics (NASDAQ:RPTX - Get Free Report) last released its quarterly earnings data on Friday, November 14th. The company reported $0.08 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.35) by $0.43. The firm had revenue of $11.62 million for the quarter, compared to the consensus estimate of $7.50 million. As a group, analysts forecast that Repare Therapeutics will post -2.04 EPS for the current fiscal year.</p>
<div class="lb-trans"><p>Repare Therapeutics（納斯達克代碼：RPTX - 獲取免費報告）最近在 11 月 14 日（星期五）發佈了季度財報。該公司報告每股收益（EPS）為 0.08 美元，超過分析師共識預期的（0.35 美元）0.43 美元。該公司季度收入為 1162 萬美元，而共識預期為 750 萬美元。整體來看，分析師預測 Repare Therapeutics 在當前財政年度將發佈-2.04 的每股收益。</p>
</div><h2>Repare Therapeutics Company Profile</h2>
<div class="lb-trans"><h2>Repare Therapeutics 公司簡介</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（獲取免費報告）</p>
</div><p>Repare Therapeutics Inc, a clinical-stage precision oncology company, engages in the discovery and development of therapeutics by using its synthetic lethality approach in Canada and the United States. It uses its SNIPRx, a proprietary, genome-wide, and CRISPR-enabled platform, to discover, validate, and build a pipeline of SL-based therapeutics that focuses on genomic instability, including DNA damage repair.</p>
<div class="lb-trans"><p>Repare Therapeutics Inc. 是一家臨牀階段的精準腫瘤學公司，致力於通過在加拿大和美國使用其合成致死方法來發現和開發治療藥物。它利用其 SNIPRx，這是一種專有的、全基因組的、基於 CRISPR 的平台，來發現、驗證並建立以 SL 為基礎的治療藥物管道，重點關注基因組不穩定性，包括 DNA 損傷修復。</p>
</div><h2>Featured Stories</h2>
<div class="lb-trans"><h2>精選故事</h2>
</div><ul>
<li>Five stocks we like better than Repare Therapeutics</li>
<li>Bank Stocks - Best Bank Stocks to Invest In</li>
<li>Attention Income Investors: This REIT Is on Sale</li>
<li>ESG Stocks, What Investors Should Know</li>
<li>Rocket Lab Just Had Its First Real Crash—The Rebound Could Be Bigger</li>
<li>Dividend Capture Strategy: What You Need to Know</li>
<li>MarketBeat Week in Review – 11/17 - 11/21</li>
</ul>
<div class="lb-trans"><ul>
<li>我們更看好的五隻股票，而不是 Repare Therapeutics</li>
<li>銀行股票 - 最值得投資的銀行股票</li>
<li>收益投資者注意：這隻 REIT 正在打折出售</li>
<li>ESG 股票，投資者需要知道的事項</li>
<li>Rocket Lab 剛經歷了第一次真正的崩潰——反彈可能會更大</li>
<li>股息捕捉策略：您需要知道的事項</li>
<li>MarketBeat 週迴顧 – 11/17 - 11/21</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9UlBUWA" alt="" original-src="https://www.marketbeat.com/scripts/RatingsChart.ashx?Prefix=NASDAQ&amp;Symbol=RPTX"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即時新聞警報由敍事科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快的報道和公正的覆蓋。請將任何問題或意見發送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Repare Therapeutics Right Now?</h2>
<div class="lb-trans"><h2>你現在應該投資 1,000 美元在 Repare Therapeutics 嗎？</h2>
</div><p>Before you consider Repare Therapeutics, you'll want to hear this.</p>
<div class="lb-trans"><p>在考慮 Repare Therapeutics 之前，您需要聽聽這個。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Repare Therapeutics wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦的股票。MarketBeat 已識別出五隻頂級分析師正在悄悄向客户推薦的股票，建議在更廣泛的市場注意到之前立即購買……而 Repare Therapeutics 並不在名單上。</p>
</div><p>While Repare Therapeutics currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>雖然 Repare Therapeutics 目前在分析師中獲得了持有評級，但頂級分析師認為這五隻股票更值得購買。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>查看這五隻股票</p>
</div>

Repare Therapeutics Inc. (NASDAQ:RPTX) 獲得分析師一致推薦 “持有” 評級